SANUWAVE Health, Inc.
NASDAQ:SNWVMedical - Devices
+$0.18 today
- Market cap
- $51.01M
- Beta
- 1.34
- P/E (TTM)
- 5.0
- EPS (TTM)
- $1.87
Volume 0.04M
Average 0.11M
SNWV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
SANUWAVE Health, Inc.NASDAQ: SNWV
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $660K rose 217.3% year over year, ahead of the +151.4% change in trailing-twelve-month research & development. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at +33.6% a year.
Context
- Research & development amounted to 3.1% of revenue in FY2025, up 1.0 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +217.3% holds above the trailing-twelve-month pace of +151.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.35M USD
- Year-over-year change
- +101.0%
- 4-year CAGR
- +5.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.35M | +101.0% |
| FY2024 | 2024-12-31 | 673K | +16.2% |
| FY2023 | 2023-12-31 | 579K | +2.1% |
| FY2022 | 2022-12-31 | 567K | -48.5% |
| FY2021 | 2021-12-31 | 1.1M | — |
Research & Development vs competitors
How SNWV compares with its peers on the latest reported figures
- SNWV's LTM Mar 2026 research & development of $1.81M is the lowest of the 11 companies compared; the peer median is $20.9M.
- Its year-over-year change of +151.4% is the 2nd highest of 11, against a peer median of -11.4%.
- Research & development amounts to 4.1% of revenue for SNWV, versus a peer median of 24.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $33.21M | -3.4% | +10.2% | 22.9% | |
| LTM Mar 2026 | $32.9M | -13.4% | -7.3% | 80.8% | |
| LTM Mar 2026 | $21.34M | -31.8% | -24.3% | 18.1% | |
| LTM Mar 2026 | $20.46M | +7.3% | -4.0% | 5.8% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| LTM Mar 2026 | $13.97M | -23.1% | -7.7% | 24.2% | |
| LTM Mar 2026 | $12.72M | -28.5% | -13.9% | 16.0% | |
| LTM Mar 2026 | $2.57M | -32.8% | -6.3% | 26.8% | |
| LTM Mar 2026 | $1.81M | +151.4% | +33.6% | 4.1% | |
| Peer median (excluding SNWV) | $20.9M | -11.4% | -7.1% | 24.2% | |
Competitors are the stored peer set for SNWV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.01M | 16.74M | 20.4M | 32.63M | 44.05M |
| Cost of Revenue | 4.99M | 4.33M | 6.04M | 8.08M | 10.08M |
| Gross Profit | 8.02M | 12.41M | 14.36M | 24.55M | 33.97M |
| Gross Margin | 61.7% | 74.1% | 70.4% | 75.2% | 77.1% |
| Research & Development | 1.1M | 567K | 579K | 673K | 1.35M |
| Selling, General & Admin | 20.28M | 20.03M | 13.57M | 17.67M | 26.79M |
| Operating Expenses | 22.17M | 21.36M | 14.9M | 19.13M | 29.02M |
| Depreciation & Amortization | 1.24M | 952K | 1.03M | 1.15M | 1.28M |
| EBITDA | (18.9M) | 4.79M | (9.15M) | (16.56M) | 19.43M |
| EBITDA Margin | -145.3% | 28.6% | -44.9% | -50.8% | 44.1% |
| Operating Income | (14.14M) | (8.95M) | (540K) | 5.42M | 4.95M |
| Operating Margin | -108.7% | -53.5% | -2.6% | 16.6% | 11.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 7.1M | 14.13M | 15.62M | 13.64M | 6.25M |
| Other Income / Expenses | (13.09M) | (1.34M) | (25.26M) | (36.76M) | 6.95M |
| Income Before Tax | (27.23M) | (10.29M) | (25.8M) | (31.35M) | 11.9M |
| Pre-Tax Margin | -209.3% | -61.5% | -126.5% | -96.1% | 27.0% |
| Income Tax Expense | 28K | 2K | 4K | 27K | 86K |
| Net Income | (27.26M) | (10.29M) | (25.81M) | (31.37M) | 11.81M |
| Net Margin | -209.5% | -61.5% | -126.5% | -96.1% | 26.8% |
| EPS (Basic) | (19.72) | (7.02) | (12.19) | (7.03) | 1.38 |
| EPS (Diluted) | (19.72) | (7.02) | (12.19) | (7.03) | 0.41 |
| Weighted Avg Shares | 1.38M | 1.47M | 2.12M | 4.46M | 8.56M |
| Weighted Avg Shares (Diluted) | 1.38M | 1.47M | 2.12M | 4.46M | 9.08M |
SANUWAVE Health, Inc.
NASDAQ:SNWV
Intrinsic Alpha fair value
Locked
Current Price
$5.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.